{
    "clinical_study": {
        "@rank": "124520", 
        "arm_group": [
            {
                "arm_group_label": "tOPV commercial batch (Bio Farma)", 
                "arm_group_type": "Active Comparator", 
                "description": "tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)"
            }, 
            {
                "arm_group_label": "tOPV pilot batch", 
                "arm_group_type": "Experimental", 
                "description": "tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the antibody response 30 days after two doses of t\n      OPV"
        }, 
        "brief_title": "Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The trial design is phase II, randomized, double blind, prospective intervention study. The\n      subject study are 240 healthy, full term, newborn infants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, full term, newborns infants\n\n          -  newborn residing within a relatively short and easily accessible distance A(<30km)\n             from the study clinic(s) and not planning to travel away during the entire study\n             period\n\n          -  Infant born after 37 weeks of pregnancy\n\n          -  Infant weighing 2.5kg or more at birth (birth weight >= 2.5kg)\n\n          -  Healthy newborns, with no history of asphyxia or meconium aspiration\n\n          -  Father, mother or legally acceptable representative properly informed about the study\n             and having signed the informed consent form.\n\n          -  Parents will commit themselves to comply with the indications of the investigator and\n             with the schedule of the trial\n\n          -  Mother at least elementary school graduate\n\n        Exclusion Criteria:\n\n          -  Child concomitantly enrolled or scheduled to be enrolled in another trial\n\n          -  Known history of congenital or acquired immunodeficiency (including HIV infection)\n\n          -  Evolving moderate or severe illness, especially infectious diseases or fever\n             (axillary temperature >=37.5oC\n\n          -  Newborns requiring hospitalization at birth\n\n          -  Infant immunized with non-scheduled OPV or IPV during trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "1 Day", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093273", 
            "org_study_id": "OPV 0213"
        }, 
        "intervention": [
            {
                "arm_group_label": "tOPV pilot batch", 
                "description": "the tOPV vaccine is given orally", 
                "intervention_name": "tOPV pilot batch", 
                "intervention_type": "Biological", 
                "other_name": "tOPV (Bio Farma)"
            }, 
            {
                "arm_group_label": "tOPV commercial batch (Bio Farma)", 
                "description": "tOPV vaccine is given orally", 
                "intervention_name": "tOPV commercial batch", 
                "intervention_type": "Biological", 
                "other_name": "tOPV (Bio Farma)"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "tOPV", 
            "Antibody response", 
            "Safety"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Garuda Primary Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Ibrahim Adjie Primary Health Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Puter Primary Health Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Padasuka Primary Health Centre"
                }
            }
        ], 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II, Randomized, Double Blind, Prospective Intervention Study to Evaluate the Immunogenicity and Safety Profile of tOPV (Bio Farma) With Different Batch Numbers in Indonesian Infants", 
        "other_outcome": {
            "description": "Measurement of titer antibody", 
            "measure": "To describe the antibody response after two doses of tOPV", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "overall_official": {
            "affiliation": "Department of Child Health of Medicine Padjadjaran University", 
            "last_name": "Eddy Fadlyana, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "antibody titer to Polio", 
            "measure": "To compare the antibody response 30 days after two doses of tOPV", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093273"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Data collection of local and systemic reaction after immunization", 
            "measure": "To asses and compare the safety of tOPV", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "source": "PT Bio Farma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PT Bio Farma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}